SavedAdd your journal

Journals / MN Oftalmoloji / 2008 / Cilt: 15 - Sayı: 2

Investigation of plasminogen activator ınhibitor-1 (pai-1) gene 4g/5g polymorphism in pseudoexfoliation glaucoma

Psödoeksfolyasyon glokomunda plazminojen aktivatör inhibitör-1 (pai-1) gen 4g/5g poliformizminin araştırılması

Oya TEKELİ
Emine ÇATAK
Duygu ÖZEL
Nejat AKAR
Pages
82–84
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In this study, we could not find any association between PAI-1 4G/5G gene polymorphism and PEX glaucoma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To investigate the possible association between the plasminogen activator inhibitor-1 (PAI-1) gene polymorphism and pseudoexfoliation (PEX) glaucoma.
📊
Key Findings & Data:Material and Method: This study consisted of 78 patients with PEX glaucoma, and 100 controls.
💡
Conclusion & Impact:Conclusion: In this study, we could not find any association between PAI-1 4G/5G gene polymorphism and PEX glaucoma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To investigate the possible association between the plasminogen activator inhibitor-1 (PAI-1) gene polymorphism and pseudoexfoliation (PEX) glaucoma. Material and Method: This study consisted of 78 patients with PEX glaucoma, and 100 controls. All participants underwent a complete ophthalmic examination. PAI-1 gene polymorphism was evaluated with the polymerase chain reaction method. Results: There was no statistically significant difference in patient and control groups for the age and sex. PAI-1 gene polymorphism did not show significant difference between the patients with PEX glaucoma. Conclusion: In this study, we could not find any association between PAI-1 4G/5G gene polymorphism and PEX glaucoma.

Özet

Amaç: Psödoeksfolyasyon (PEX) glokomu ve PAI-1 gen polimorfizmi arasındaki olası birlikteliği araştırmak. Gereç ve Yöntem: Çalışmaya PEX glokomlu 78 hasta ve 100 kontrol alındı. Tüm olgulara tam bir oftalmolojik muayene yapıldı. PAI-1 gen polimorfizmi polimeraz zincir reaksiyonu yöntemi ile değerlendirildi. Bulgular: Hasta ve kontrol grubunda yaş ve cinsiyet açısından istatistiksel olarak anlamlı fark yoktu. PAI-1 gen polimorfizmi PEX glokom hastaları ve kontrol olguları arasında anlamlı fark göstermedi (p=0.566). Sonuç: Bu çalışmada PAI-1 4G/5G gen polimorfizmi ile PEX glokom arasında herhangi bir bağ bulamadık.

🔖

Cite This Article

TEKELİ, O., ÇATAK, E., ÖZEL, D., AKAR, N. (2008). Investigation of plasminogen activator ınhibitor-1 (pai-1) gene 4g/5g polymorphism in pseudoexfoliation glaucoma. MN Oftalmoloji, Cilt: 15 - Sayı: 2, 82–84. https://ajindex.com/articles/296781

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Ritch R. Exfoliation syndrome. Curr Opin Ophthalmol 2001; 12:124-30
  2. Netland PA, Ye H, Streeten BW, Hernadez MR. Elastosis of the lamina cribrosa in pseudoexfoliation syndrome with glaucoma. Ophthalmology 1995;102:878-86
  3. Dan J, Belyea D, Gertner G, Lehsem I, Lusky M, Miskin R. Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma. Arch Ophthalmol 2005; 123:220-4
  4. Meyer MW, Von Depka M, Wilhelm C, Schröder A, Erb C. Plasminogen activator inhibitor-1 mRNA expression in cultured pigmented ciliary epithelial cells of the porcine eye. Graefes Arch Clin Exp Ophthalmol 2002;240:679-86
  5. Akar N, Yılmaz E, Akar E, Avcu F, Yalçın A, Cin Ş. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A.Thromb Res 2000;15;97:227-30
  6. Acott TS. Trabecular extracellular matrix regulation. In: Drance SM, Van Buskirk EM, Neufeld AH, editors. Pharmacology of glaucoma. Baltimore;Wiliams and Wilkins. 1992;125-7
  7. Nagase H. mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151-60
  8. Jeng JR. Association of PAI-1 gene promoter 4G/5G polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension.Am J Hypertens 2003;16:290-296
  9. Juhan-Vaguen I, Morange PE, Frere C, et al. The plasminogen activator inhibitor -1-675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe:the HIFMECH study. J Thromb Haemost 2003;1:2322-9
  10. Schlötzer-Schrehardt U, Lommatzsch J, Küchle M, Konstas AG, Naumann O. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2003;44:1117-25
  11. Mossböck G, Weger M, Faschinger C, Schmut O, Renner W. Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma. Mol Vis 2008;14:1240-4.